AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.